LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches ("TTS"​) and Oral Thin Films ("OTF"​) for the pharmaceutical industry. While we continuously refine our TTS and OTF technologies further, we also research complementary Micro Array Patches for the transdermal delivery of large molecule, biological actives. Incorporated in 1984, we operate today from two sites in Andernach, Germany and West Caldwell/NJ, USA, plus representative office in Shanghai/China.

Orexo is a pharmaceutical company based in Uppsala, Sweden initially financed with venture capital provided by HealthCap. The company was founded in 1995 and their first product Diabact UBT, a breath test for diagnosing the causative agent of stomach ulcers (Helicobacter pylori), was introduced in 2000. In 2003, the company adopted the name Orexo and in 2005 the company was listed on the Stockholm Stock Exchange.On March 29, 2019 a U.S. jury rejected a claim by Sweden’s Orexo AB that two generic opioid-addiction treatments created by Teva Pharmaceutical Industries Ltd. infringed a patent for Orexo’s biggest drug, Zubsolv.

Part of Indivior PLC, Indivior UK Ltd. is a company headquartered in Hull, UK, that manufactures and distributes pharmaceutical products. It was founded in 2010.

Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany.

Pierre Fabre Médicament SA manufactures cosmetics and pharmaceutical products. It focuses on research, development, and prescription of medicines and cosmetics. The company was founded on December 31, 1982 and is headquartered in Boulogne-Billancourt, France.

Avigen, Inc., a biopharmaceutical company, engages in identifying and developing products to treat patients with neurological and other disorders. The company develops the AV411 portfolio, which includes the phase II-stage lead drug compound and proprietary analogs and represents novel, non-opioid drugs for the treatment of various large pain and drug addiction indications. AV411 is an orally bioavailable small molecule; a glial attenuator that suppresses pro-inflammatory cytokines IL-1 beta, TNF alpha, and IL-6; and a toll-like receptor 4 (TLR4) functional antagonist that may contribute to its attenuation of neuroinflammation. AV411 is being evaluated in Phase Ib/IIa clinical trials. The company was founded in 1992 and is headquartered in Alameda, California. As of December 18, 2009, Avigen, Inc. operates as a subsidiary of MediciNova Inc

BioDelivery Sciences is a pharmaceutical company that focuses on pain management and addiction medicine. They are utilizing their novel and proprietary BioErodible MucoAdhesive (BEMA) drug delivery technology to develop and commercialize, either on their own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

Handan Pharmaceutical Co. Ltd. is a Chinese private company that wholesales pharmaceutical products.

Part of Tris Pharma, Inc., Park Therapeutics, Inc. is a company headquartered in Morristown, NJ, that develops drugs for treatment of pain. The firm was founded by Marc L. Lesnick and James Hackworth. James Hackworth is currently the CEO of the company. On April 29, 2021 Tris Pharma, Inc. acquired Park Therapeutics, Inc.

DemeRx, Inc. provides biotechnology services. It focuses on drug addiction among patients coping with chronic pain. The company was founded by Deborah C. Mash on March 1, 2010 and is headquartered in Miami, FL.

CV Therapeutics, Inc. operates as a research-based biopharmaceutical company. The Company researches and manufactures drugs for the treatment of cardiovascular disease and more specifically angina pectoris. CV Therapeutics serves the healthcare industry in the United States. CV Therapeutics developed Ranexa, a drug to treat chronic angina; and Lexiscan, an injection used as a stress agent in cardiovascular procedures. The company was acquired by Gilead Sciences, the maker of H.I.V. drugs Truvada, Viread, and Atriplia, for about $1.4 billion.

Xalud Therapeutics, Inc. develops novel therapies with several promising therapeutic programs for inflammatory. The firm offers XT-101, a single dosage injection that stops disease progression, eliminates neuropathic pain, and reverses paralysis. It also researches on the applicability of XT-101 for multiple sclerosis and amyotrophic lateral sclerosis. The company was founded by John Forsayeth and Linda Watkins and is headquartered in San Francisco, CA.

R.P. Scherer GmbH & Co. KG, part of Catalent, Inc., is a company headquartered in Eberbach, Germany, that develops, manufactures and sells pharmaceutical products.

Reckitt Benckiser Healthcare (UK) Ltd., a subsidiary of Reckitt Benckiser Group Plc, is a British company located in Slough. The firm manufactures household and sanitary goods. It was founded in 1931.\nThe company says this about itself: The principal activity of the company which is a Member of the Reckitt Benckiser group of companies is the manufacture and sale of branded consumer products for sale to other Group companies.

Glaxo Group Ltd. operates through its subsidiary Glaxo Laboratories Ltd. that engages in the production of food products for infants such as Ostermilk, Complan, Casilan, Farex. Glaxo Group Ltd. was formerly known as Glaxo Laboratories Ltd. and changed its name to Glaxo Group Ltd. in 1962. The company is based in Brentford, United Kingdom. Glaxo Group Ltd. operates as a subsidiary of Glaxosmithkline plc.

Camurus AB operates as a research based pharmaceutical company. The firm engages in the research, development and commercialization of specialty medicines. It provides its products for the treatment of severe and chronic conditions, which includes opioid dependence, pain, cancer and endocrine disorders. The company was founded by Kare Larsson in 1991 and is headquartered in Lund, Sweden.

AIKO Biotechnology, Inc. provides commercial physical research solutions and services. It offers treatment for pain and the side effects associated with prescription pain reliever (opioid) use, such as opioid-induced bowel dysfunction, addiction, and abuse. The company was founded in 2006 and is headquartered in Portland, ME.